Glenmark Pharmaceuticals Ltd (NSE:GLENMARK)
₹ 1194.15 -15.7 (-1.3%) Market Cap: 336.71 Bil Enterprise Value: 330.69 Bil PE Ratio: 0 PB Ratio: 4.29 GF Score: 83/100

Q2 2022 Glenmark Pharmaceuticals Ltd Earnings Call Transcript

Nov 15, 2021 / 03:00AM GMT
Release Date Price: ₹535.75 (+2.28%)
Operator

Ladies and gentlemen, good day, and welcome to the Q2 FY '22 Earnings Conference Call of Glenmark Pharmaceuticals Limited. (Operator Instructions) Please note that this conference is being recorded.

I would now like to hand the conference over to Mr. Ravi Agrawal. Thank you, and over to you, sir.

Ravi Agrawal
Glenmark Pharmaceuticals Limited - IR Officer

Yes. Thank you, moderator. A warm good morning to everyone, and welcome to the Q2 FY '22 Results Conference Call of Glenmark Pharmaceuticals Limited.

Before we start the call, a review of the operations of the company. For the second quarter of FY '21/'22, Glenmark's consolidated revenue was at INR 31,474 million as against INR 29,525 million, recording an increase of 6.6% year-on-year. For the 6 months ending September 30, 2021, Glenmark's consolidated revenue was at INR 61,123 million as against INR 52,973 million, recording an increase of 15.4% year-on-year.

On to the businesses. First, the India business. Sales from the formulation business in India in Q2 FY '22 was at INR 9

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot